Who is sponsoring NCT06184464?

NCT06184464 is sponsored by Consorci Sanitari de Terrassa.

What drugs are being tested in NCT06184464?

Interventions in NCT06184464: ACETATE LEUPRELINE.

What condition does NCT06184464 study?

NCT06184464 studies Prostate Cancer Adenocarcinoma, Prostate Adenocarcinoma.

Is NCT06184464 still recruiting?

NCT06184464 is currently recruiting now. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06184464: PROSTSIZE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostatic Size Reduction Following of Leuprorelin Acetate

Recruiting now Last updated 19 September 2024

What this trial tests

trial testing ACETATE LEUPRELINE in Prostate Cancer Adenocarcinoma in 40 participants. Currently enrolling.

Timeline

2 February 2024

Primary endpoint
15 December 2024

15 December 2024

Quick facts

Lead sponsor	Consorci Sanitari de Terrassa
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	40
Start date	2 February 2024
Primary completion	15 December 2024
Estimated completion	15 December 2024
Sites	1 location across Spain

Drugs / interventions tested

ACETATE LEUPRELINE

Conditions studied

Prostate Cancer Adenocarcinoma — all drugs for Prostate Cancer Adenocarcinoma →
Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →

Sponsor

Consorci Sanitari de Terrassa — full company profile →

Who can join

Adults 18 to 95, male only, with Prostate Cancer Adenocarcinoma or Prostate Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

CT-Based Quantification of Prostate Volume Change After LHRH-Agonist Androgen Deprivation: A Prospective, Three-Reader Study for Radiotherapy Planning.
Feltes Benítez N, Galdeano-Rubio M, Muñoz-Rodriguez J, Domínguez A, et al · · 2025 · PMID 41598185 · DOI 10.3390/life16010029

Verify or expand the search:

Other Consorci Sanitari de Terrassa trials

Trials by the same sponsor.

NCT07467408 — Treatment of Mechanical Low Back Pain With High-Intensity Focused Ultrasound (HIFU) · not yet recruiting
NCT07210892 — Paramedian Incidence Angles in Spinal Anaesthesia · recruiting
NCT06956794 — Multimodal Training With Immersive Virtual Reality to Improve the Cognitive Health and Emotional Well-being of Older Wom · NA · active not recruiting
NCT06713460 — Emotional Intelligence Intervention to Improve Mental Well-Being of Adolescents With Emotional Distress (BEAM) · NA · recruiting
NCT07040748 — Immersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06184464 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Consorci Sanitari de Terrassa
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06184464.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing